# US 2026/0263410 A1 · Use of calcium sensing receptor antagonists for treating ocular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0263410 A1
- Document ID: US20260263410A1
- Status: Published application
- Kind: A1
- Application number: 19/491,385
- Filed: 2024-06-07
- Published: 2026-09-10
- Earliest claimed: 2023-06-09
- Applicants: The Regents of the University of California
- Inventors: Onur CIL; Neel PASRICHA
- Web page: https://patentgrep.com/patent/US20260263410A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/275: Nitriles; Isonitriles
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/195: having an amino group
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein include therapy for treating ocular disorders such as dry eye disease by targeting calcium sensitive receptor (CaSR), a regulator of ocular surface ion transport.

## Claims

### Claim 1

A method for treating ocular surface disorders in a subject in need thereof, the method comprising administrating to the subject a pharmaceutical composition comprising a calcium sensitive receptor (CaSR) antagonist and an ophthalmically acceptable excipient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the pharmaceutical composition is applied to an eye of the subject.

### Claim 3 (depends on 2)

The pharmaceutical method of claim 2 wherein the pharmaceutical composition is applied to an eye of the subject every 4-12 hours, or preferably, every 6-8 hours.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ocular surface disorder is one or more dye eye diseases, keratoconjunctivitis, keratitis, or Sjogren's syndrome.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is applied as eye drops, punctal plug, subconjunctival injectable, or through fluid-eluting contact lens.

### Claim 6 (depends on 1)

The method of claim 1, wherein the CaSR antagonist has an IC50 value of 10 μM or less.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CaSR antagonist is 2-chloro-6-[(2R)-3-([1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino)-2-hydroxypropoxy]benzonitrile (NPS-2143), ronacaleret, encaleret NPS-2390, NPSP-795 (or SB-423562), calcium-sensing receptor antagonists I, Calhex 231, ligustroflavone, SB-423557, or CaSR antagonist-1.

### Claim 8

A method for increasing tear production in a subject in need thereof, the method comprising administrating to the subject a pharmaceutical composition comprising a calcium sensitive receptor (CaSR) antagonist and an ophthalmically acceptable excipient.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pharmaceutical composition is applied to an eye of the subject.

### Claim 10 (depends on 8)

The method of claim 8 wherein the pharmaceutical composition is applied to an eye of the subject every 4-12 hours, or preferably, every 6-8 hours.

### Claim 11 (depends on 8)

The method of claim 8, wherein the CaSR antagonist has an IC50 value of 10 μM or less.

### Claim 12 (depends on 11)

The method of claim 11 wherein the CaSR antagonist is 2-chloro-6-[(2R)-3-([1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino)-2-hydroxypropoxy]benzonitrile (NPS-2143), ronacaleret, encaleret NPS-2390, NPSP-795 (or SB-423562), calcium-sensing receptor antagonists I, Calhex 231, ligustroflavone, SB-423557, or CaSR antagonist-1.

### Claim 13

A topical ophthalmic formulation for use in treating ocular surface disorders or increasing tear production, the ophthalmic formulation comprising a calcium sensitive receptor (CaSR) antagonist and an ophthalmically acceptable excipient.

### Claim 14 (depends on 13)

The topical ophthalmic formulation of claim 13, wherein the ocular surface disorders include dry eye diseases, keratoconjunctivitis, keratitis, or Sjogren's syndrome.

### Claim 15 (depends on 13)

The topical ophthalmic formulation of claim 13, wherein the CaSR antagonist has an IC50 value of 10 μM or less, and preferably, 2-chloro-6-[(2R)-3-([1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino)-2-hydroxypropoxy]benzonitrile (NPS-2143), ronacaleret, encaleret NPS-2390, NPSP-795 (or SB-423562), calcium-sensing receptor antagonists I, Calhex 231, ligustroflavone, SB-423557, or CaSR antagonist-1.
